Current Clinical Pharmacology

Continued as Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

Arduino A. Mangoni
Flinders University and Flinders Medical Centre
Adelaide, SA
(Australia)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 6 Issue: 3, August

Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)]

Volume:6   Issue: 3
Pp: 143-143
Ulka Vaishampayan
DOI: 10.2174/157488411797189370
Published on: 01 March, 2012

Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma

Volume:6   Issue: 3
Pp: 144-150
Michel Choueiri, Nizar Tannir and Eric Jonasch
DOI: 10.2174/157488411797189415
Published on: 01 March, 2012

Immunotherapy of Kidney Cancer

Volume:6   Issue: 3
Pp: 151-163
Petros D. Grivas and Bruce G. Redman
DOI: 10.2174/157488411797189406
Published on: 01 March, 2012

VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives

Volume:6   Issue: 3
Pp: 164-168
Toni K. Choueiri
DOI: 10.2174/157488411797189424
Published on: 01 March, 2012

Therapy for Non-Clear Cell Histologies in Renal Cancer

Volume:6   Issue: 3
Pp: 169-180
Rhonda L. Bitting, John Madden and Andrew J. Armstrong
DOI: 10.2174/157488411797189460
Published on: 01 March, 2012

Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

Volume:6   Issue: 3
Pp: 181-188
Priti Patel and Sandy Srinivas
DOI: 10.2174/157488411797189442
Published on: 01 March, 2012

Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma

Volume:6   Issue: 3
Pp: 189-198
Marc R. Matrana, Bradley Atkinson, Eric Jonasch and Nizar M. Tannir
DOI: 10.2174/157488411797189398
Published on: 01 March, 2012

Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development

Volume:6   Issue: 3
Pp: 199-206
Neal Rasmussen and W. Kimryn Rathmell
DOI: 10.2174/157488411797189389
Published on: 01 March, 2012

Immunotherapy and Targeted Therapy Combinations in Renal Cancer

Volume:6   Issue: 3
Pp: 207-213
David F. McDermott
DOI: 10.2174/157488411797189451
Published on: 01 March, 2012

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

Volume:6   Issue: 3
Pp: 214-221
Holleh D. Husseinzadeh and Jorge A. Garcia
DOI: 10.2174/157488411797189433
Published on: 01 March, 2012